Entering text into the input field will update the search result below

CytoDyn: Suitable For Trading Not Investing

May 06, 2021 7:29 AM ETCytoDyn Inc. (CYDY)202 Comments
Out of Ignorance profile picture
Out of Ignorance


  • In 2019, CytoDyn touted initial approval of leronlimab as a blockbuster combination therapy for HIV.
  • CytoDyn has encountered a long string of obstacles in presenting leronlimab to the FDA for its consideration.
  • Leronlimab's current status in its quest for approval as combination therapy is a developing situation.
  • The ebb and flow of CytoDyn's new and exciting projects have a familiar cadence.
  • CytoDyn's finances have been touch and go for the bulk of its existence.

Alice in Wonderland - Cheshire Cat
Photo by duncan1890/DigitalVision Vectors via Getty Images

The Cheshire Cat ... constantly grins and can disappear and reappear whenever it likes. Sometimes it disappears and leaves its grin behind.

Fool me once, shame on you; fool me twice shame on me. Fool me

Data by YCharts

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Analyst’s Disclosure: I am/we are long CYDY. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may buy or sell shares in any stock mentioned over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.